NCT02468739View on ClinicalTrials.gov

Effect of GM1 in Prevention of Taxanes Induced Neurotoxicity in Operable Breast Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

206

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

November 30, 2016

Study Completion Date

December 31, 2016

Conditions
Breast Cancer
Interventions
DRUG

Ganglioside-monosialic acid

Ganglioside-monosialic sodium is added into to 250 ml of 0.9% sodium chloride injection, which is given once a day via intravenous drip infusion for 3 days. The first dose is given at 1 day before the start of the chemotherapy.(day -1, day 1 and day2). The dosages of GM1 are 80mg per day.

DRUG

placebo

Placebo is added into to 250 ml of 0.9% sodium chloride injection, which is given once a day via intravenous drip infusion for 3 days. The first dose is given at 1 day before the start of the chemotherapy.(day -1, day 1 and day2).

Trial Locations (1)

510060

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER

NCT02468739 - Effect of GM1 in Prevention of Taxanes Induced Neurotoxicity in Operable Breast Cancer | Biotech Hunter | Biotech Hunter